ADC Therapeutics SA

conference will start momentarily. Once again, thank you for your patience. The conference will start momentarily. THE END Thank you. Thank you. Welcome to the ADC Therapeutics Second Quarter 2021 Financial Results Conference Call. My name is Victor, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session. During the question and answer session, If you have a question, please press star, then 1 on your touchtone phone. I will now turn the call over to Amanda Hamilton, Investor Relations Manager. Amanda, you may begin.

Thank you, Operator. This morning, we issued a press release announcing our second quarter 2021 financial results and business updates. This release is available on the ADCT website at ir.adctherapeutics.com under the Press Releases section. On today's call, Chris Martin, Chief Executive Officer, Jennifer Herron, Chief Commercial Officer, Jay Feingold, Chief Medical Officer, and Jen Creel, Chief Financial Officer, will discuss recent business highlights and review our second quarter 2021 financial results before opening the call for questions. As a reminder, this conference call may contain forward-looking statements. Those statements are subject to risks and uncertainties. For additional information concerning forward-looking statements and factors that could cause actual results to differ materially from those expressed or implied in these statements, we refer you to the section titled Cautionary Statement Regarding Forward-Looking Statements in Exhibit 99.3 of our report on Form 6-K filed with the U.S. Securities and Exchange Commission earlier today. Such statements speak only as of the date of this conference call, and we expressly disclaim any obligation or undertaking to update these forward-looking statements unless required to do so by applicable law. Today's presentation also includes non-IFRS financial measures. These non-IFRS measures have limitations as financial measures and should be considered in addition to and not in isolation or as a substitute for the information prepared in accordance with IFRS. you should refer to the information contained in the company's second quarter earnings release for definitional information and reconciliations of historical non-IFRS measures to the comparable IFRS financial measures. It is now my pleasure to pass the call over to our CEO, Chris Martin.

Chris? Thanks, Amanda, and thank you, everyone, for joining us today. The second quarter was nothing less than transformative for our company as we received our first accelerated FDA approval and bought SymLonta with its broad label and differentiated profile to this area of high unmet medical need. We achieved key objectives across the board, including commercial, clinical development, and corporate development goals. Let's start with our first commercial product. In April, we received accelerated FDA approval for Zinlanta for our first indication in relapsed refractory DLBCL and became a fully integrated biopharma company. Today, it's early in the launch and we're pleased with our progress and the positive reception from the physician and payer communities. Jennifer Herron, our Chief Commercial Officer, will share more details about our launch a little later in this call. On the R&D front, we continue to advance our pipeline programs, which we expect to also drive long-term value for the company. We presented new data at ASCO and ICML on a few of our key programs, including updated duration of response for the pivotal Zinlanta Phase 2 Lotus 2 trial and the Phase 1 trial of Zinlanta in combination with Ibrutinib. We also presented encouraging interim data for the phase two trial of our second program, CAMI, in Hodgkin lymphoma. Jay will elaborate further on these and our other programs in a few moments. We are also focused on expanding our geographic footprint, providing long-term as many patients as possible worldwide. As you know, we formed the joint venture Overland ADCT Biopharma to develop and commercialize four of our products, including Zinlanca, in Greater China and Singapore. The joint venture has made tremendous progress, including the hire of a CEO, Eric Koo, who has substantial experience in China. Eric and his team are now making rapid progress towards initiating a pivotal bridging study. As for Europe, we have recently engaged with EU regulators And based on that feedback, we plan to submit a marketing authorization application to the EMA in the second half of 2021. We are evaluating all of our go-to-market options and look forward to updating you on our plans for Europe when we have more specific details to share. I would now like to turn the call over to Jennifer to provide some insights from the early days of the Zinlonson launch. Jennifer.